Shanghai Fosun Pharmaceutical (600196.SH): The drug registration application for Sodium Hyaluronate Injection has been approved.
Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary Chongqing Kailin Pharmaceutical Co., Ltd. has obtained the approval from the National Medical Products Administration for the drug registration application of Sodium Thiosulfate Injection. This approval is for the treatment of cyanide poisoning, as well as arsenic, mercury, lead, bismuth, iodine, and other poisonings.
Shanghai Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Chongqing Kailin Pharmaceutical Co., Ltd. has obtained approval from the National Medical Products Administration for the drug registration application of Sodium Thiosulfate Injection. The approved indications for this drug include use in cyanide poisoning, as well as in poisoning from arsenic, mercury, lead, bismuth, iodine, and others.
Related Articles
Shanghai Fosun Pharmaceutical (02196): Sodium Thiosulfate Injection Approved for Registration
Yum China (09987) spent HK$7.712 million on March 19 to repurchase 18,200 shares.
XIAOMI-W (01810) spent 99.99 million Hong Kong dollars to repurchase 2.975 million shares on March 20th.
Shanghai Fosun Pharmaceutical (02196): Sodium Thiosulfate Injection Approved for Registration
Yum China (09987) spent HK$7.712 million on March 19 to repurchase 18,200 shares.
XIAOMI-W (01810) spent 99.99 million Hong Kong dollars to repurchase 2.975 million shares on March 20th.
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
